Even before this current Pandemic, Influenza kills tens of thousands of individuals in the UK every year.
This is important information to patients aged 50-64 years who have been invited to have the Flublok influenza immunisation from January 2021 onwards.
We are required to inform you that this vaccine does not currently have a UK marketing authorisation, but has been authorised for temporary supply in the UK by the Medicines and Health Regulatory Agency (MHRA) and has been licensed and used in the USA since 2013 and that it is being offered in accordance with national guidance.
By agreeing to have the Flublok flu immunisation, you are agreeing that you are happy to receive this new immunisation that does not currently have a UK marketing authorisation and that this is being closely monitored for new unknown safety information.
- Flublok is a flu (influenza) vaccine for adults who are 18 years of age and older. It will be used as part of the UK’s 2020/21 seasonal flu programme from December.
- Flublok is made by Sanofi and is licensed for use in the USA by the Food and Drug Administration (FDA). It has been used there since 2016 and has been distributed to over 9 million people. The FDA considers the vaccine safe and acceptable for use.
- Flublok has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency (MHRA) for immunisation against flu in this year’s seasonal flu programme to meet public health need.
Published: Jun 15, 2021